Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 1355693.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly over-represented in the NMS group.
Medical subject headings
- Antipsychotic Agents
- Bipolar Disorder
- Hospitalization
- Neuroleptic Malignant Syndrome
- Schizophrenia
- Schizophrenic Psychology